Intellectual property
The patent application for TL-532 and a new family of TLR3 ligands was filed by TOLLYS in 2018 (EP 18305561).
Tollys
Triggering & installing efficient anti-tumor immunity
Office
60 avenue Rockefeller
69008 Lyon, FRANCE